JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online October 16, 2009, 10.2967/jnumed.109.065284
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
jnumed.109.065284v1
50/11/1887    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Choi, S. R.
Right arrow Articles by Kung, H. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, S. R.
Right arrow Articles by Kung, H. F.
Journal of Nuclear Medicine Vol. 50 No. 11 1887-1894
© 2009 by Society of Nuclear Medicine
doi: 10.2967/jnumed.109.065284

Basic Science Investigation

Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain

Seok Rye Choi1, Geoff Golding1, Zhiping Zhuang1, Wei Zhang1, Nathaniel Lim1, Franz Hefti1, Tyler E. Benedum1, Michael R. Kilbourn2, Daniel Skovronsky1,3 and Hank F. Kung3,4

1 Avid Radiopharmaceutical Inc., Philadelphia, Pennsylvania; 2 Department of Radiology, University of Michigan, Ann Arbor, Michigan; 3 Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania; and 4 Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania

Correspondence: For correspondence or reprints contact: Hank F. Kung, 3700 Market St., Ste 305, Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104. E-mail: kunghf{at}gmail.com

β-amyloid plaques (Aβ plaques) in the brain, containing predominantly fibrillary Aβ peptide aggregates, represent a defining pathologic feature of Alzheimer disease (AD). Imaging agents targeting the Aβ plaques in the living human brain are potentially valuable as biomarkers of pathogenesis processes in AD. (E)-4-(2-(6-(2-(2-(2-18F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine (18F-AV-45) is such as an agent currently in phase III clinical studies for PET of Aβ plaques in the brain. Methods: In vitro binding of 18F-AV-45 to Aβ plaques in the postmortem AD brain tissue was evaluated by in vitro binding assay and autoradiography. In vivo biodistribution of 18F-AV-45 in mice and ex vivo autoradiography of AD transgenic mice (APPswe/PSEN1) with Aβ aggregates in the brain were performed. Small-animal PET of a monkey brain after an intravenous injection of 18F-AV-45 was evaluated. Results: 18F-AV-45 displayed a high binding affinity and specificity to Aβ plaques (Kd, 3.72 ± 0.30 nM). In vitro autoradiography of postmortem human brain sections showed substantial plaque labeling in AD brains and not in the control brains. Initial high brain uptake and rapid washout from the brain of healthy mice and monkey were observed. Metabolites produced in the blood of healthy mice after an intravenous injection were identified. 18F-AV-45 displayed excellent binding affinity to Aβ plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice. The results lend support that 18F-AV-45 may be a useful PET agent for detecting Aβ plaques in the living human brain.

Key Words: PET imaging • Alzheimer disease • β-amyloid plaque • autoradiography • biodistribution

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.